Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiten Vora

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Diabetes Care|January 1, 2013
Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureasMelanie Davies, Simon Heller, Seamus Sreenan, et al.
Journal of Diabetes and Its Complications|June 29, 2017
Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisalJiten Vora, Kausik Ray, Mikhail Kosiborod, et al.
Current Medical Research and Opinion|May 24, 2011
Impact of weight gain on outcomes in type 2 diabetesStuart A Ross, Grzegorz Dzida, Jiten Vora, et al.
Journal of Nephrology|July 13, 2002
Painful cutaneous lesions, renal failure and urgent parathyroidectomyNaveed Younis, Robert A Sells, Anthony Desmond, et al.
Endocrine Journal|May 24, 2008
Lymphocytic hypophysitis occurring simultaneously with a functioning pituitary adenomaDaniel J Cuthbertson, Dave Ritchie, Daniel Crooks, et al.
Diabetes, Obesity & Metabolism|January 4, 2021
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trialsLindsay E Clegg, Yankang Jing, Robert C Penland, et al.
Diabetes Research and Clinical Practice|May 13, 2015
Clinical use of insulin degludecJiten Vora, Bertrand Cariou, Marc Evans, et al.
Diabetes, Obesity & Metabolism|February 8, 2024
Inter-relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and managementJiten Vora, David Cherney, Mikhail N Kosiborod, et al.
American Journal of Nephrology|December 9, 2019
Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes MellitusDavid Z I Cherney, Enrico Repetto, David C Wheeler, et al.
BMC Endocrine Disorders|April 27, 2022
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVERSuzanne V Arnold, Fengming Tang, Andrew Cooper, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Diabetes Care|January 1, 2013
Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureasMelanie Davies, Simon Heller, Seamus Sreenan, et al.
Journal of Diabetes and Its Complications|June 29, 2017
Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisalJiten Vora, Kausik Ray, Mikhail Kosiborod, et al.
Current Medical Research and Opinion|May 24, 2011
Impact of weight gain on outcomes in type 2 diabetesStuart A Ross, Grzegorz Dzida, Jiten Vora, et al.
Journal of Nephrology|July 13, 2002
Painful cutaneous lesions, renal failure and urgent parathyroidectomyNaveed Younis, Robert A Sells, Anthony Desmond, et al.
Endocrine Journal|May 24, 2008
Lymphocytic hypophysitis occurring simultaneously with a functioning pituitary adenomaDaniel J Cuthbertson, Dave Ritchie, Daniel Crooks, et al.
Diabetes, Obesity & Metabolism|January 4, 2021
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trialsLindsay E Clegg, Yankang Jing, Robert C Penland, et al.
Diabetes Research and Clinical Practice|May 13, 2015
Clinical use of insulin degludecJiten Vora, Bertrand Cariou, Marc Evans, et al.
Diabetes, Obesity & Metabolism|February 8, 2024
Inter-relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and managementJiten Vora, David Cherney, Mikhail N Kosiborod, et al.
American Journal of Nephrology|December 9, 2019
Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes MellitusDavid Z I Cherney, Enrico Repetto, David C Wheeler, et al.
BMC Endocrine Disorders|April 27, 2022
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVERSuzanne V Arnold, Fengming Tang, Andrew Cooper, et al.
Pageof 5